« Back
Home /
Neoandrographolide

Neoandrographolide

Item no.	TMO-T3884-5mg
Manufacturer	TargetMol
CASRN	27215-14-1
Amount	5 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 1 mL 200 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Oncology Reagents & Chemicals Molecules By Organ Breast Cancer
Type	Molecules
Specific against	other
Citations	1. Yang T,et al. Hypolipidemic effects of andrographolide and neoandrographolide in mice and rats. Phytother Res. 2013 Apr;27(4):618-23.
Smiles	C[C@@]1(CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)CCC[C@@]2(C)[C@H](CCC3=CCOC3=O)C(=C)CC[C@H]12
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	Neoandrographiside
Shipping Condition	Cool pack
Available
Manufacturer - Targets	NOS\|\|\|COX
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	480.59
Description	Neoandrographolide (Neoandrographiside) has potent hypolipidemic effect and protects the cardiovascular without significant liver damage.Neoandrographolide has anti-inflammatory effect, might result from inhibition of iNOS and COX-2 expression through inhibiting p38 MAPKs activation.Neoandrographolide as chemosensitizer in S-Jurkat and X chromosome-linked inhibitor of apoptosis protein (XIAP)-overexpressing Jurkat cells, a model for chemoresistance.
Pathways	Neuroscience\|\|\|Immunology/Inflammation

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T3884-5mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question